Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2485

1.

Opioid Analgesics in Georgia Medicaid: Trends in Potential Inappropriate Prescribing Practices by Demographic Characteristics, 2009-2014.

Jayawardhana J, Abraham AJ, Perri M.

J Manag Care Spec Pharm. 2018 Sep;24(9):886-894. doi: 10.18553/jmcp.2018.24.9.886.

2.

Modeling Health Benefits and Harms of Public Policy Responses to the US Opioid Epidemic.

Pitt AL, Humphreys K, Brandeau ML.

Am J Public Health. 2018 Oct;108(10):1394-1400. doi: 10.2105/AJPH.2018.304590. Epub 2018 Aug 23.

PMID:
30138057
3.

Pharmacotherapy, Resource Needs, and Physician Recruitment Practices in Substance Use Disorder Treatment Programs.

Knudsen HK, Brown R, Jacobson N, Horst J, Kim JS, Collier E, Starr S, Madden LM, Haram E, Molfenter T.

J Addict Med. 2018 Aug 7. doi: 10.1097/ADM.0000000000000441. [Epub ahead of print]

PMID:
30095565
4.

Commentary on "The More Things Change: Buprenorphine/Naloxone Diversion Continues While Treatment is Inaccessible".

Mitchell SG, Gryczynski J, Schwartz RP.

J Addict Med. 2018 Aug 7. doi: 10.1097/ADM.0000000000000437. [Epub ahead of print]

PMID:
30095564
5.

The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible.

Carroll JJ, Rich JD, Green TC.

J Addict Med. 2018 Aug 7. doi: 10.1097/ADM.0000000000000436. [Epub ahead of print]

PMID:
30095563
6.

Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.

Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI.

J Neuroimmune Pharmacol. 2018 Aug 9. doi: 10.1007/s11481-018-9801-x. [Epub ahead of print]

PMID:
30094695
7.

Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.

Schroeder JR, Phillips KA, Epstein DH, Jobes ML, Furnari MA, Kennedy AP, Heilig M, Preston KL.

Psychopharmacology (Berl). 2018 Aug 6. doi: 10.1007/s00213-018-4986-5. [Epub ahead of print]

PMID:
30079432
8.

Addressing Intersecting Housing and Overdose Crises in Vancouver, Canada: Opportunities and Challenges from a Tenant-Led Overdose Response Intervention in Single Room Occupancy Hotels.

Bardwell G, Fleming T, Collins AB, Boyd J, McNeil R.

J Urban Health. 2018 Aug 2. doi: 10.1007/s11524-018-0294-y. [Epub ahead of print]

PMID:
30073598
9.

Endocannabinoid-Enhanced "Liking" in Nucleus Accumbens Shell Hedonic Hotspot Requires Endogenous Opioid Signals.

Mitchell MR, Berridge KC, Mahler SV.

Cannabis Cannabinoid Res. 2018 Jul 1;3(1):166-170. doi: 10.1089/can.2018.0021. eCollection 2018.

10.

Characterizing peer roles in an overdose crisis: Preferences for peer workers in overdose response programs in emergency shelters.

Bardwell G, Kerr T, Boyd J, McNeil R.

Drug Alcohol Depend. 2018 Sep 1;190:6-8. doi: 10.1016/j.drugalcdep.2018.05.023. Epub 2018 Jun 26.

PMID:
29960202
11.

Preventing Opioid Overdose in the Clinic and Hospital: Analgesia and Opioid Antagonists.

Peglow SL, Binswanger IA.

Med Clin North Am. 2018 Jul;102(4):621-634. doi: 10.1016/j.mcna.2018.02.005. Review.

PMID:
29933819
12.

Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review.

Behar E, Bagnulo R, Coffin PO.

Prev Med. 2018 Sep;114:79-87. doi: 10.1016/j.ypmed.2018.06.005. Epub 2018 Jun 15. Review.

13.

Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.

Socías ME, Wood E, Kerr T, Nolan S, Hayashi K, Nosova E, Montaner J, Milloy MJ.

Drug Alcohol Depend. 2018 Aug 1;189:90-95. doi: 10.1016/j.drugalcdep.2018.04.026. Epub 2018 May 29.

PMID:
29894910
14.

Patient predictors of substance use disorder treatment initiation in primary care.

Ober AJ, Watkins KE, McCullough CM, Setodji CM, Osilla K, Hunter SB.

J Subst Abuse Treat. 2018 Jul;90:64-72. doi: 10.1016/j.jsat.2018.04.004. Epub 2018 Apr 28.

PMID:
29866385
15.

National Institute on Drug Abuse International Program: improving opioid use disorder treatment through international research training.

Gust SW, McCormally J.

Curr Opin Psychiatry. 2018 Jul;31(4):287-293. doi: 10.1097/YCO.0000000000000426.

16.

Post-stroke Intranasal (+)-Naloxone Delivery Reduces Microglial Activation and Improves Behavioral Recovery from Ischemic Injury.

Anttila JE, Albert K, Wires ES, Mätlik K, Loram LC, Watkins LR, Rice KC, Wang Y, Harvey BK, Airavaara M.

eNeuro. 2018 Apr 18;5(2). pii: ENEURO.0395-17.2018. doi: 10.1523/ENEURO.0395-17.2018. eCollection 2018 Mar-Apr.

17.

Community-Based Response to Fentanyl Overdose Outbreak, San Francisco, 2015.

Rowe C, Wheeler E, Stephen Jones T, Yeh C, Coffin PO.

J Urban Health. 2018 May 3. doi: 10.1007/s11524-018-0250-x. [Epub ahead of print]

PMID:
29725887
18.

A community pharmacy intervention for opioid medication misuse: A pilot randomized clinical trial.

Cochran G, Field C, Karp J, Seybert AL, Chen Q, Ringwald W, Hruschak V, Chickering S, Kincman J, Jaber A, Tarter R.

J Am Pharm Assoc (2003). 2018 Jul - Aug;58(4):395-403. doi: 10.1016/j.japh.2018.03.005.

PMID:
29691197
19.

Coverage of Medications That Treat Opioid Use Disorder and Opioids for Pain Management in Marketplace Plans, 2017.

Huskamp HA, Riedel LE, Barry CL, Busch AB.

Med Care. 2018 Jun;56(6):505-509. doi: 10.1097/MLR.0000000000000918.

PMID:
29668645
20.

Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.

Dunn KE, Barrett FS, Bigelow GE.

Addict Behav. 2018 Nov;86:56-60. doi: 10.1016/j.addbeh.2018.03.011. Epub 2018 Mar 28.

PMID:
29625751

Supplemental Content

Loading ...
Support Center